Dr Fischer and colleagues assessed the clinical relevance of the tumor node metastasis (TNM), and World Health Organization classifications in patients with pancreatic neuroendocrine tumors.
The researchers prospectively collected data from 118 consecutive patients with a pancreatic neuroendocrine tumors receiving surgical intervention.
|5-year survival rates were 95% for well differentiated neuroendocrine tumors|
|The British Journal of Surgery|
The team found that 41 patients had well differentiated neuroendocrine tumors, 64 had well differentiated neuroendocrine carcinomas, and 13 had poorly differentiated neuroendocrine carcinomas.
The research team observed that 5-year survival rates were 95%, and 44% for well differentiated neuroendocrine tumors and carcinomas, respectively.
For poorly differentiated neuroendocrine carcinomas, the 5-year survival rate was 0%.
There was no difference in survival after R0 and R1/R2 resections in patients with neuroendocrine carcinomas.
In those with well differentiated neuroendocrine carcinomas, any resection and having a clinically non-functional tumour significantly increased survival.
The team found the tumor node metastasis stage was I in 37 patients, II in 15 patients, III in 32 patients and IV in 34 patients.
There were significant differences in 5-year survival between stage I and II, being 88% and 85%, respectively.
The 5-year survival for stage III was 31%, and for stage IV it was 42%.
Dr Fischer's team concluded, "Both classifications accurately reflect the clinical outcome of patients with pancreatic neuroendocrine tumors."
"The resection status may not be critical for long-term survival in patients with pancreatic neuroendocrine tumors."